The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of Hepatitis B virus (HBV) infection, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against HBV infection. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate HBV infection in infected cells or as a vaccine for the prevention of disease.

The present invention provides designed polypeptides that selectively bind to and inhibit Epstein Barr protein BHFR1, and B cell lymphoma family proteins, and are thus useful for treating Epstein Barr-related diseases and cancer.

The present invention provides designed polypeptides that selectively bind to and inhibit Epstein Barr protein BHFR1, and B cell lymphoma family proteins, and are thus useful for treating Epstein Barr-related diseases and cancer.

The present invention relates to a cell model for diseases associated with corneal neovascularization by using Epstein Barr virus (EBV)-infected human corneal epithelial cells (HCECs). Provided are a method for preparing a cell model for diseases associated with corneal neovascularization by using EBV-infected HCECs, the method including: infecting HCECs with EBV; culturing the infected HCECs; and determining whether the cultured HCECs are infected with EBV. In addition, provided is a method for screening diseases associated with corneal neovascularization prepared by the cell model for diseases associated with corneal neovascularization.

This invention relates to the rapid determination of the viral titer by contacting a solution comprising viral particles, such as lentiviral particles, comprising a heterologous envelope protein, such as VSV-G, with an immobilised receptor that binds to the envelope protein, and determining the binding of the viral particles to be immobilised receptor using surface plasmon resonance (SPR).

Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Hepatitis B Virus infection in mammals, and to methods of using those compositions of matter for the same.

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of Hepatitis B virus (HBV) infection, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against HBV infection. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate HBV infection in infected cells or as a vaccine for the prevention of disease.

Systems and methods for detecting a substance in a fluid and detecting a condition based on the substance in the fluid are described herein. Electromagnetic radiation travels through tapered fibers while substance is bound to the tapered fibers. The phase change of the electromagnetic radiation caused by the bound substance is used to detect the substance in the fluid and to predict the likelihood of a condition based on the bound substance.

The invention describes a method to identify and stage human herpesvirus-mediated neurodegenerations by measuring secreted herpesvirus protein and RNA levels in a blood sample and comparing that level to an individual's baseline or reference level. Combining herpesvirus secretome levels with other neurodegeneration biomarkers, such as coagulation factors and cell adhesion molecules, can aid in diagnosis and staging of neuropathology. Sensitive and economical ELISA diagnostic kits can detect and quantify the herpesvirus secretome and neurodegeneration biomarkers to diagnose herpesvirus-mediated neurodegeneration, stage disease, and predict disease progression. Finally, this method will elucidate herpesvirus-mediated neurodegenerations and aid in developing therapeutics.

The present invention relates to a method of detecting the presence of Cytomegalovirus and measuring antigenicity through detection and quantification of a pentameric complex by an indirect sandwich ELISA assay which ensures an appropriate concentration of this critical glycoprotein complex is present in the vaccine.